INCB57643
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for INCB57643, covering 2025-05-22 to 2025-05-22. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis [Phase 2]